Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy


Por: Talla, A, Azevedo, JLLC, Latif, MB, Enriquez, AB, Sanchez, GP, Pelletier, AN, Bal, SK, Kumari, S, Schuch, V, Ghneim, K, Rhodes, A, Maldarelli, F, Yarchoan, R, Lurain, K, Ramaswami, R, Sharon, E, Hess, BW, D'Amico, L, Martinez-Picado, J, Chomont, N, Lewin, SR, Deeks, SG, Fling, SP, Cheever, MA, Uldrick, TS, Sharma, AA and Sekaly, RP

Publicada: 1 feb 2026 Ahead of Print: 1 feb 2026
Resumen:
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1-2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGF beta. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866.

Filiaciones:
Talla, A:
 Immunasyst, Phoenix, AZ USA

Azevedo, JLLC:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

Latif, MB:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

Enriquez, AB:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

Sanchez, GP:
 West Virginia Univ, Dept Biol, Morgantown, WV USA

Pelletier, AN:
 RPM Bioinfo Solut, Montreal, PQ, Canada

Bal, SK:
 Signios Biosci Inc, Foster City, CA USA

Kumari, S:
 Takara Bio USA Inc, San Jose, CA USA

Schuch, V:
 Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA USA

Ghneim, K:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

Rhodes, A:
 Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia

Maldarelli, F:
 NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA

Yarchoan, R:
 NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA

Lurain, K:
 Ohio State Univ, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA

Ramaswami, R:
 NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD USA

Sharon, E:
 Dana Farber Canc Inst, Boston, MA USA

Hess, BW:
 Fred Hutchinson Canc Ctr, Seattle, WA USA

D'Amico, L:
 Fred Hutchinson Canc Ctr, Seattle, WA USA

:
 IrsiCaixa, Barcelona, Spain

 CIBERINFEC, Madrid, Spain

 Univ Cent Catalunya UVic UCC, Univ Vic, Barcelona, Spain

 ICREA, Barcelona, Spain

Chomont, N:
 Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada

 CHUM, Ctr Rech, Montreal, PQ, Canada

Lewin, SR:
 Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia

 Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Serv, Melbourne, Vic, Australia

 Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia

 Monash Univ, Melbourne, Vic, Australia

Deeks, SG:
 Univ Calif San Francisco, San Francisco, CA USA

Fling, SP:
 Fred Hutchinson Canc Ctr, Seattle, WA USA

Cheever, MA:
 Fred Hutchinson Canc Ctr, Seattle, WA USA

Uldrick, TS:
 Fred Hutchinson Canc Ctr, Seattle, WA USA

Sharma, AA:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

 Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA

 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

Sekaly, RP:
 Emory Univ, Sch Med, Dept Pathol, Pathol Adv Translat Res Unit, Atlanta, GA 30322 USA

 Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA

 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
ISSN: 10788956





Nature Medicine
Editorial
Nature Publishing Group, 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA, Reino Unido
Tipo de documento: Article
Volumen: 32 Número: 2
Páginas:
WOS Id: 001688407500001
ID de PubMed: 41680482
imagen Green Submitted, hybrid

MÉTRICAS